131 related articles for article (PubMed ID: 11245909)
1. Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.
Harada M; Murata J; Sakamura Y; Sakakibara H; Okuno S; Suzuki T
J Control Release; 2001 Mar; 71(1):71-86. PubMed ID: 11245909
[TBL] [Abstract][Full Text] [Related]
2. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128).
Okuno S; Harada M; Yano T; Yano S; Kiuchi S; Tsuda N; Sakamura Y; Imai J; Kawaguchi T; Tsujihara K
Cancer Res; 2000 Jun; 60(11):2988-95. PubMed ID: 10850447
[TBL] [Abstract][Full Text] [Related]
3. Carrier effects on antitumor activity and neurotoxicity of AZ10992, a paclitaxel-carboxymethyl dextran conjugate, in a mouse model.
Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
Biol Pharm Bull; 2008 Feb; 31(2):223-30. PubMed ID: 18239277
[TBL] [Abstract][Full Text] [Related]
4. Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity.
Harada M; Imai J; Okuno S; Suzuki T
J Control Release; 2000 Dec; 69(3):389-97. PubMed ID: 11102679
[TBL] [Abstract][Full Text] [Related]
5. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate.
Harada M; Sakakibara H; Yano T; Suzuki T; Okuno S
J Control Release; 2000 Dec; 69(3):399-412. PubMed ID: 11102680
[TBL] [Abstract][Full Text] [Related]
6. MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
Fujita F; Koike M; Fujita M; Sakamoto Y; Okuno S; Kawaguchi T; Yano S; Yano T; Kiuchi S; Fujiwara T; Kudoh S; Kakushima M
Clin Cancer Res; 2005 Feb; 11(4):1650-7. PubMed ID: 15746070
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
8. High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Ma H; Li X; Yang Z; Okuno S; Kawaguchi T; Yagi S; Bouvet M; Hoffman RM
J Surg Res; 2011 Dec; 171(2):684-90. PubMed ID: 20851421
[TBL] [Abstract][Full Text] [Related]
9. Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy.
Onishi H; Machida Y
Curr Drug Discov Technol; 2005 Sep; 2(3):169-83. PubMed ID: 16472226
[TBL] [Abstract][Full Text] [Related]
10. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
11. Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate.
Binaschi M; Parlani M; Bellarosa D; Bigioni M; Salvatore C; Palma C; Crea A; Maggi CA; Manzini S; Goso C
Anticancer Drugs; 2006 Nov; 17(10):1119-26. PubMed ID: 17075311
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
13. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
14. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
Masubuchi N
Pharmazie; 2004 May; 59(5):374-7. PubMed ID: 15212304
[TBL] [Abstract][Full Text] [Related]
16. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992).
Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
J Control Release; 2007 Jan; 117(1):40-50. PubMed ID: 17126446
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
Bigioni M; Parlani M; Bressan A; Bellarosa D; Rivoltini L; Animati F; Crea A; Bugianesi R; Maggi CA; Manzini S; Binaschi M
Int J Cancer; 2009 Nov; 125(10):2456-64. PubMed ID: 19536774
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
Veltkamp SA; Witteveen EO; Capriati A; Crea A; Animati F; Voogel-Fuchs M; van den Heuvel IJ; Beijnen JH; Voest EE; Schellens JH
Clin Cancer Res; 2008 Nov; 14(22):7535-44. PubMed ID: 19010872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
